<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Regeneron Pharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/regeneron-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Regeneron Pharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 23 Apr 2026 19:46:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/regeneron-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b6b278dffbe2df11432b.webp</url>
      <title>Regeneron Pharmaceuticals Inc</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-announces-agreement-with-us-government-to-help-lower-drug-costs-for-american-patients-and-will-provide-innovative-new-gene-therapy-for-free-in-the-us</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-announces-agreement-with-us-government-to-help-lower-drug-costs-for-american-patients-and-will-provide-innovative-new-gene-therapy-for-free-in-the-us</guid>
      <pubDate>Thu, 23 Apr 2026 19:46:00 GMT</pubDate>
      <description>Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid prices based on prices in other developed countries; prices for future medicines in the U.S. will be aligned with prices set in that defined group of other countries Praluent® (alirocumab), an important cardiovascular medicine, will be available for direct patient purchase through TrumpRx.gov Regeneron wi</description>
    </item>
    <item>
      <title>Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/otarmenitm-lunsotogene-parvec-cwha-approved-by-fda-as-first-and-only-gene-therapy-for-genetic-hearing-loss-regeneron-to-provide-otarmeni-for-free-in-the-us</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/otarmenitm-lunsotogene-parvec-cwha-approved-by-fda-as-first-and-only-gene-therapy-for-genetic-hearing-loss-regeneron-to-provide-otarmeni-for-free-in-the-us</guid>
      <pubDate>Thu, 23 Apr 2026 16:40:00 GMT</pubDate>
      <description>Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint, and with longer follow-up, 42% achieved normal hearing that included whispers First FDA-approved example of a gene therapy to restore a neurosensory function to normal levels Otarmeni is Regeneron’s first approved genetic medicine, showcasing its ability to advance new therapeutic</description>
    </item>
    <item>
      <title>Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dupixentr-dupilumab-approved-in-the-us-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria-csu</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dupixentr-dupilumab-approved-in-the-us-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria-csu</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID</description>
    </item>
    <item>
      <title>Telix and Regeneron Announce Strategic Radiopharma Collaboration</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/telix-and-regeneron-announce-strategic-radiopharma-collaboration</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/telix-and-regeneron-announce-strategic-radiopharma-collaboration</guid>
      <pubDate>Mon, 13 Apr 2026 10:30:00 GMT</pubDate>
      <description>Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model.Collaboration combines Telix’s expertise in radiopharmaceutical development and manufacturing with Regeneron’s leading antibody discovery/development platforms and oncology experience. Telix to receive US$40 million upfront for four initial programs with optionality on a per program basis to co-fund commercialization and profit-share or earn up to an aggre</description>
    </item>
    <item>
      <title>Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dupixentr-dupilumab-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria-csu</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dupixentr-dupilumab-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria-csu</guid>
      <pubDate>Mon, 13 Apr 2026 05:00:00 GMT</pubDate>
      <description>Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adults The latest approval expands Dupixent’s indication for CSU in the EU to children as young as 2 years; Dupixent is now approved for children less than 12 years of age across four chronic diseases driven in part by type 2 inflammation TARRYTOWN, N.Y.</description>
    </item>
    <item>
      <title>Regeneron and Telix Announce Strategic Radiopharma Collaboration</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-and-telix-announce-strategic-radiopharma-collaboration</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-and-telix-announce-strategic-radiopharma-collaboration</guid>
      <pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
      <description>Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model Collaboration</description>
    </item>
    <item>
      <title>TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/trinetx-collaborates-with-regeneron-to-access-de-identified-electronic-health-records-of-300-million-patients-to-drive-research-and-product-development-in-life-sciences-and-digital-health-solutions</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/trinetx-collaborates-with-regeneron-to-access-de-identified-electronic-health-records-of-300-million-patients-to-drive-research-and-product-development-in-life-sciences-and-digital-health-solutions</guid>
      <pubDate>Thu, 02 Apr 2026 20:30:00 GMT</pubDate>
      <description>TriNetX® and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic collaboration to support Regeneron&apos;s capabilities in drug discovery and development, as well as new initiatives to deliver digital health solutions of the future for consumers, patients and providers. Regeneron gains the exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX&apos;s industry-leading phenotypic data network of approximately 300 million de-identified and anonymized</description>
    </item>
    <item>
      <title>EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/eylea-hdr-aflibercept-approved-by-fda-as-first-and-only-injectable-anti-vegf-with-dosing-intervals-up-to-5-months-for-wet-age-related-macular-degeneration-wamd-and-diabetic-macular-edema-dme</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/eylea-hdr-aflibercept-approved-by-fda-as-first-and-only-injectable-anti-vegf-with-dosing-intervals-up-to-5-months-for-wet-age-related-macular-degeneration-wamd-and-diabetic-macular-edema-dme</guid>
      <pubDate>Thu, 02 Apr 2026 16:00:00 GMT</pubDate>
      <description>Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing regimen allows patients with wAMD and DME to be treated as infrequently as 2 to 3 times a year, further extending the widest range of dosing intervals of any approved injectable anti-VEGF TARRYTOWN, N.Y., April 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced th</description>
    </item>
    <item>
      <title>Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-collaborates-with-trinetx-to-access-de-identified-electronic-health-records-of-300-million-patients-to-drive-research-and-product-development-in-life-sciences-and-digital-health-solutions</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-collaborates-with-trinetx-to-access-de-identified-electronic-health-records-of-300-million-patients-to-drive-research-and-product-development-in-life-sciences-and-digital-health-solutions</guid>
      <pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
      <description>Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic</description>
    </item>
    <item>
      <title>Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call-and-webcast-on-april-29-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call-and-webcast-on-april-29-2026</guid>
      <pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
      <description>TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2026</description>
    </item>
    <item>
      <title>Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/press-release-sanofi-and-regenerons-dupixent-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid-1</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/press-release-sanofi-and-regenerons-dupixent-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid-1</guid>
      <pubDate>Tue, 24 Mar 2026 06:00:00 GMT</pubDate>
      <description>Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placeboBP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesionsBP is the seventh approved ind</description>
    </item>
    <item>
      <title>Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dupixentr-dupilumab-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid-bp</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dupixentr-dupilumab-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid-bp</guid>
      <pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
      <description>Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease</description>
    </item>
    <item>
      <title>Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dr-teresa-montagut-appointed-as-clinical-development-and-medical-affairs-head-at-mesoblast-1</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dr-teresa-montagut-appointed-as-clinical-development-and-medical-affairs-head-at-mesoblast-1</guid>
      <pubDate>Wed, 11 Mar 2026 23:21:00 GMT</pubDate>
      <description>NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast’s medical affairs organization, fostering clinical collaborations and spearheading investigator-ini</description>
    </item>
    <item>
      <title>Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-science-talent-search-2026-recognizes-americas-top-young-scientists-awarding-more-than-dollar18-million-to-high-school-seniors-for-innovative-research-in-computational-mathematics-neural-science-and-blood-cancer-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-science-talent-search-2026-recognizes-americas-top-young-scientists-awarding-more-than-dollar18-million-to-high-school-seniors-for-innovative-research-in-computational-mathematics-neural-science-and-blood-cancer-treatment</guid>
      <pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
      <description>$250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competition TARRYTOWN, N.Y. and WASHINGTON, March</description>
    </item>
    <item>
      <title>Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/olatorepatide-obesity-treatment-licensed-by-regeneron-demonstrates-positive-phase-3-results-in-chinese-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/olatorepatide-obesity-treatment-licensed-by-regeneron-demonstrates-positive-phase-3-results-in-chinese-patients</guid>
      <pubDate>Mon, 09 Mar 2026 11:00:00 GMT</pubDate>
      <description>Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its Phase 3 trial in Chinese patients evaluating olatorepatide for the treatment of adults with obesity or who are overweight. Olatorepati</description>
    </item>
    <item>
      <title>Regeneron Announces Investor Conference Presentation</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-announces-investor-conference-presentation-60</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-announces-investor-conference-presentation-60</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation at the Barclays 28th</description>
    </item>
    <item>
      <title>Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/press-release-sanofi-and-regenerons-dupixent-recommended-for-eu-approval-to-treat-chronic-spontaneous-urticaria-in-young-children-with-ongoing-symptoms-despite-treatment-1</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/press-release-sanofi-and-regenerons-dupixent-recommended-for-eu-approval-to-treat-chronic-spontaneous-urticaria-in-young-children-with-ongoing-symptoms-despite-treatment-1</guid>
      <pubDate>Fri, 27 Feb 2026 12:03:00 GMT</pubDate>
      <description>Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children Paris and Tarryt</description>
    </item>
    <item>
      <title>Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dupixentr-dupilumab-recommended-for-eu-approval-to-treat-chronic-spontaneous-urticaria-csu-in-young-children-with-ongoing-symptoms-despite-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dupixentr-dupilumab-recommended-for-eu-approval-to-treat-chronic-spontaneous-urticaria-csu-in-young-children-with-ongoing-symptoms-despite-treatment</guid>
      <pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
      <description>If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by</description>
    </item>
    <item>
      <title>Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-renews-sponsorship-of-the-regeneron-science-talent-search-through-2036-committing-an-additional-dollar150-million-to-empower-the-next-generation-of-science-and-technology-leaders</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/regeneron-renews-sponsorship-of-the-regeneron-science-talent-search-through-2036-committing-an-additional-dollar150-million-to-empower-the-next-generation-of-science-and-technology-leaders</guid>
      <pubDate>Thu, 26 Feb 2026 17:03:00 GMT</pubDate>
      <description>Regeneron Renews its Science Talent Search Sponsorship for Another 10 Years Regeneron is renewing the title sponsorship of the Regeneron Science Talent Search, the United States’ oldest and most prestigious science and mathematics competition for high school seniors. The company is committing $150 million for the next 10 years. Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for S</description>
    </item>
    <item>
      <title>Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)</title>
      <link>https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dupixentr-dupilumab-approved-in-the-us-as-the-first-and-only-medicine-for-allergic-fungal-rhinosinusitis-afrs</link>
      <guid isPermaLink="true">https://6ix.com/company/regeneron-pharmaceuticals-inc/news/dupixentr-dupilumab-approved-in-the-us-as-the-first-and-only-medicine-for-allergic-fungal-rhinosinusitis-afrs</guid>
      <pubDate>Tue, 24 Feb 2026 14:30:00 GMT</pubDate>
      <description>Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven in part by type 2 infl</description>
    </item>
  </channel>
</rss>